Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Alberta Health services

Status and phase: Completed; Phase 2

Conditions: Thyroid Neoplasms

Treatments: Procedure: IMRT

Study type: Interventional

Funder types: Other

Identifiers

NCT00279721

18916

Details and patient eligibility

About

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Full description

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion criteria

• medullary or anaplastic thyroid cancer, unresectable

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)